Injective (INJ) is currently priced at $3.01, reflecting a slight decline of 1.52% over the past 24 hours. The trading range has been tight, with a high of $3.08 and a low of $2.98, indicating low volatility in the market.

The trading volume stands at approximately 35.9 million, representing 11.97% of the market cap, which suggests healthy trading activity relative to its size. The hourly moving averages indicate a bearish short-term sentiment, with the 8 SMA showing a minor decline of 0.15%, while the longer SMAs reflect mixed signals with some support seen at the 55 SMA ($2.98) and 144 SMA ($2.93).

The 1-hour RSI is critically low at 24, suggesting that INJ is oversold in the very short term. Conversely, the 7-day RSI at 57 indicates a more balanced market condition, supporting the idea of potential price recovery in the near term, especially considering the recent upward trends observed over the past week (7-day price change: +7.78%).

Fundamentally, INJ is well below its all-time high of $52.62, reached earlier in the year, which suggests significant upside potential if market conditions improve. The recent price changes over 14 days (+4.11%) and 30 days (+0.58%) indicate a generally positive trajectory, although the latest 24-hour performance reflects some selling pressure.

Given the oversold condition indicated by the low 1-hour RSI, combined with relatively stable support levels from longer-term moving averages, there exists a potential for a price rebound. Therefore, the recommendation for Injective (INJ) is a Buy, as the market shows signs of stabilization and possible recovery, particularly if volume remains strong and broader market sentiment improves.